Swiss National Bank lowered its position in Zoetis Inc. (NYSE:ZTS) by 1.3% during the third quarter, Holdings Channel reports. The fund owned 1,307,180 shares of the company’s stock after selling 16,700 shares during the period. Swiss National Bank’s holdings in Zoetis were worth $67,986,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of ZTS. Vanguard Group Inc. increased its position in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the last quarter. Independent Franchise Partners LLP increased its position in shares of Zoetis by 1.6% in the third quarter. Independent Franchise Partners LLP now owns 11,361,033 shares of the company’s stock worth $590,887,000 after buying an additional 177,286 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Zoetis by 0.9% in the second quarter. Principal Financial Group Inc. now owns 9,890,168 shares of the company’s stock worth $469,388,000 after buying an additional 92,034 shares during the last quarter. Marshall Wace LLP increased its position in shares of Zoetis by 1.9% in the second quarter. Marshall Wace LLP now owns 9,159,978 shares of the company’s stock worth $434,733,000 after buying an additional 173,902 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Zoetis by 114.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,738,248 shares of the company’s stock worth $414,717,000 after buying an additional 4,656,765 shares during the last quarter. Institutional investors and hedge funds own 92.41% of the company’s stock.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Shares of Zoetis Inc. (NYSE:ZTS) opened at 50.45 on Wednesday. The company has a market cap of $24.91 billion, a PE ratio of 36.37 and a beta of 1.05. The company’s 50-day moving average is $50.03 and its 200 day moving average is $49.67. Zoetis Inc. has a 52-week low of $38.26 and a 52-week high of $53.14.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.46 by $0.06. The company earned $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The company’s quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. On average, analysts anticipate that Zoetis Inc. will post $1.94 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be issued a $0.095 dividend. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Tuesday, November 1st. Zoetis’s dividend payout ratio is currently 27.54%.

TRADEMARK VIOLATION NOTICE: This report was published by Daily Political and is the propert of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international copyright law. The correct version of this report can be accessed at http://www.dailypolitical.com/2016/11/30/swiss-national-bank-sells-16700-shares-of-zoetis-inc-zts.html.

ZTS has been the topic of a number of recent analyst reports. Jefferies Group restated a “buy” rating and set a $60.00 target price on shares of Zoetis in a report on Tuesday, August 23rd. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Thursday, October 6th. Guggenheim reiterated a “positive” rating and issued a $60.00 price objective on shares of Zoetis in a report on Monday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 price objective on shares of Zoetis in a report on Wednesday, October 12th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $53.00 price objective on shares of Zoetis in a report on Thursday, November 3rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $55.92.

In related news, insider Roxanne Lagano sold 9,797 shares of the stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $50.43, for a total value of $494,062.71. Following the transaction, the insider now directly owns 8,063 shares in the company, valued at approximately $406,617.09. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kristin C. Peck sold 10,092 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the transaction, the insider now owns 22,768 shares in the company, valued at $1,128,154.40. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.